

> 流行病學


# BREAST CANCER

流行病學

• In U.S., most common cancer in women; 2nd leading cause of cancer death in women

• **Genetic risk:** 15–20% ⊕ FHx → 2× ↑ risk; ~45% familial cases a/w germline mutation

### BRCA1/2:** 35–85% lifetime risk of breast ca & ↑ risk of ovarian** & prostate ca; ? ↑ colon ca; BRCA2: ↑ _male_ breast, prostate & pancreatic ca. Germline loss-of-function mutations in _PALB2_ a/w 35% ↑ risk breast cancer by age 70 (_NEJM_ 2014;371:497).

• **Estrogen:** ↑ risk with early menarche, late menopause, late parity or nulliparity (_NEJM_ 2006;354:270); ↑ risk with prolonged HRT (RR = 1.24 after 5.6 y; _JAMA_ 2003;289:3243); OCP use a/w extremely low to no ↑ risk (_NEJM_ 2017:317:2228; _JAMA Oncol_ 2018;4:516)

• Benign breast conditions: ↑ risk if atypia (atypical ductal or lobular hyperplasia; _NEJM_ 2015;372:78) or proliferative (ductal hyperplasia, papilloma, radial scar, or sclerosing adenosis) features; _no_ ↑ risk with cysts, simple fibroadenoma, or columnar changes

• ↑ risk with h/o ionizing radiation to chest for 治療 of Hodgkin lymphoma

Prevention (if high-risk: eg, FHx, LCIS, atypical hyperplasia)

• Tamoxifen (contraindic. in preg): ↓ risk contralat. breast ca as adjuvant Rx. Approved for 1° prevent. if ↑ risk: ↓ invasive breast cancer, but ↑ DVT & uterine ca.

• Raloxifene (only if post-menopausal): ↓ risk of invasive breast ca & vertebral fx, ↑ risk of stroke & DVT/PE (_NEJM_ 2006;355:125); less effective than tamoxifen in prevention of breast ca but lower risk of VTE, cataracts, & uterine ca (_Ann Int Med_ 2013;158:604)

• Aromatase inhib. (post-menopausal): ↓ risk >50% (_Lancet_ 2014;383:1041), ↑ osteoporosis

• _BRCA1/2_ ⊕: intensified surveillance vs. prophylactic bilat. mastectomy which ↓ risk ~90%; bilat. salpingo-oophorectomy ↓ risk of ovarian _and_ breast cancer (_NEJM_ 2016;374:454)

臨床表現

• Breast mass (hard, irregular, fixed, nontender), nipple discharge (higher risk if unilateral, limited to 1 duct, bloody, associated with mass)

• Special types: **Paget** disease → unilateral nipple eczema + nipple discharge; **inflammatory** breast cancer → skin erythema and edema _(peau d’orange)_

• Metastases: lymph nodes, bone, liver, lung, brain

Screening (_JAMA_ 2015;314:1599; _Annals_ 2019;170:547)

• **Mammography:** ~20–30% ↓ **in breast cancer mortality**, smaller abs. benefit in women <50 y (_JAMA_ 2018;319:1814); digital breast tomosynthesis (3-D) ↑ specificity (_JAMA Oncol_ 2019;5:635); suspicious findings: clustered **microcalcifications**, **spiculated**, **enlarging**

• ACS recommends annual mammo beginning at age 45 (consider biennial after age 54)

• USPSTF recommends beginning at 50 and biennially (some may want to begin at age 40)

• ↑ risk: screen earlier with exam and mammo (age 25 in _BRCA1/2_ carrier, 5–10 y before earliest FHx case, 8–10 y after thoracic RT, upon dx of ↑ risk benign disease)

• **MRI:** superior to mammo in high-risk and young 病人; consider annually if >20% lifetime risk (eg, ⊕ FHx, _BRCA1/2_, prior chest RT) (_Lancet_ 2011;378:1804)

• **Genetic testing:** recommended in women with strong FHx (_NCCN_ v2.2019)

Diagnostic evaluation

• **Palpable breast mass:** age <30 y → observe for resolution over 1–2 menstrual cycles; age <30 y, unchanging mass → **U**/**S** → aspiration if mass not simple cyst;

age >30 y _or_ solid mass on U/S _or_ bloody aspirate _or_ recurrence after aspiration → **mammo** (detect other lesions) _and_ either **fine-needle asp.** or **core-needle bx**

clearly cancerous on exam or indeterminate read or atypia on bx → **excisional bx**

• **Suspicious mammogram** with normal exam: stereotactically guided bx

• MRI: detects contralateral cancer in 3% of 病人 with recently dx breast cancer & contra-lateral mammo (but PPV only 21%) (_NEJM_ 2007;356:1295); utility remains unclear

Staging

• **Anatomic:** tumor size, chest wall invasion, axillary LN mets (_strongest prognostic factor_)

• **Histopathologic:** type (little prognostic relevance) & grade; lymphatic/vascular invasion

### _In situ_ carcinoma: no invasion of surrounding stroma

### Ductal (DCIS): ↑ risk of invasive cancer in _ipsilateral_ breast (~30%/10 y)

### Lobular (LCIS): marker of ↑ risk of invasive cancer in _either_ breast (~1%/y)

### Invasive carcinoma: infiltrating ductal (70–80%); invasive lobular (5–10%); tubular, medullary and mucinous (10%, better prognosis); papillary (1–2%); other (1–2%)

### Inflammatory breast cancer (see above): not a histologic type but a 臨床reflection of tumor invasion of dermal lymphatics; very poor prognosis

### Paget disease (see above)**:** ductal cancer invading nipple epidermis ± associated mass

• **Biomarkers:** estrogen, progesterone receptor (ER/PR) and HER2/_neu_ amplification

• Oncotype DX 21-gene expression recurrence score is predictive & prognostic in ER ⊕, HER2 ⊖, node ⊖ cancers (_NEJM_ 2018;379:111); also 70-gene profile (_NEJM_ 2016;375:717)

![](https://i.imgur.com/udxIuHG.jpg)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>General Approach to 治療</b> <span>(</span><span><i>JAMA</i></span> <span>20</span><span>1</span><span>9;32</span><span>1</span><span>:288 &amp;</span> <span>1</span><span>7</span><span>1</span><span>6)</span></p></td></tr><tr><td><p><b>LCIS</b></p></td><td><p>Close surveillance ± chemoprevention (often tamoxifen) <span>(</span><span><i>JCO</i></span> <span>20</span><span>1</span><span>5;33:3945)</span></p></td></tr><tr><td><p><b>DCIS</b></p></td><td><p>Mastectomy or lumpectomy ± RT ± chemoprevention <span>(</span><span><i>Lancet</i></span> <span>20</span><span>1</span><span>6;387:849 &amp; 866)</span></p></td></tr><tr><td><p><b>I</b></p></td><td><p>Surgery + RT</p></td></tr><tr><td><p><b>II</b></p></td><td><p>+ adjuvant chemo if ↑ risk: tumor &gt;2 cm <i>or</i> ⊕ LN <i>or</i> ER/PR ⊖ <i>or</i> Oncotype DX ≥31</p><p>+ hormonal Rx for ER/PR ⊕: add ovarian suppression if ↑ risk <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>8; 379:</span><span>1</span><span>22)</span></p><p>+ anti-<i>HER2</i> Rx and chemo if <i>HER2</i> ⊕ and tumor ≥1 cm or ⊕ LN</p></td></tr><tr><td><p><b>III</b></p></td><td><p>Neoadjuvant chemo → surgery + RT ± adjuvant chemotherapy</p><p>+ hormonal Rx for ER/PR ⊕: add ovarian suppression if premenopausal</p><p>+ anti-<i>HER2</i> Rx for <i>HER2</i> ⊕: usually trastuzumab + pertuzumab</p></td></tr><tr><td><p><b>IV</b></p></td><td><p>ER/PR ⊕: combined aromatase &amp; CDK4/6 inhibitors <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>6; 375:</span><span>1</span><span>925)</span></p><p>ER/PR ⊖: <i>HER2</i> ⊕ → chemo + anti-<i>HER2</i> therapy; <i>HER2</i> ⊖ → chemotherapy</p><p>Bony mets: bisphosphonates &amp; denosumab ↓ fractures <span>(</span><span><i>Cochrane</i></span> <span>20</span><span>1</span><span>7;CD003474)</span></p></td></tr></tbody></table>

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Surgery and Radiation for Local Control</b></p></td></tr><tr><td><p><b>Intervention</b></p></td><td><p><b>Indication</b></p></td></tr><tr><td><p>Breast conserving</p></td><td><p>Stage I-II, lumpectomy + sentinel lymph node biopsy<a id="st8"></a><a href="text/part0010_split_014.html#sst8">*</a> + RT</p></td></tr><tr><td><p>Modified radical mastectomy</p></td><td><p>Large tumor relative to breast, multicentric dis., prior chest RT, diffuse microcalcifications, ⊕ margins after lumpectomy</p></td></tr><tr><td><p>Post mastectomy radiation</p></td><td><p>≥4 ⊕ LN, tumor &gt;5 cm, ⊕ surgical margins, chest wall or skin involvement <span>(</span><span><i>Lancet</i></span> <span>20</span><span>1</span><span>4;384:</span><span>1</span><span>848)</span></p></td></tr></tbody></table>

[\*](text/part0010_split_014.html#st8)Axillary lymph node dissection indicated for palpable axillary LNs

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Systemic Therapy</b></p></td></tr><tr><td><p><b>Indic.</b></p></td><td><p><b>Class</b></p></td><td><p><b>Examples</b></p></td></tr><tr><td rowspan="3"><p>ER/PR ⊕</p><p><span>(</span><span><i>Lancet</i></span> <span>20</span><span>1</span><span>7;389: 2403)</span></p></td><td><p>Endo <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>9;380:</span> <span>1</span><span>226)</span></p></td><td><p><b>Tamoxifen:</b> adjuvant Rx for low risk pre-meno; ↓ recurrence &amp; ↓ mortality; 10 y superior to 5 y <span>(</span><span><i>Lancet</i></span> <span>20</span><span>11</span><span>;378:77</span><span>1</span> <span>&amp; 20</span><span>1</span><span>3;38</span><span>1</span><span>:805)</span></p><p><b>Aromatase inhibitor</b> (AI; anastrozole, letrozole, exemestane): adjuvant Rx for post-meno; ↑ OS vs. tam. <span>(</span><span><i>Lancet</i></span> <span>20</span><span>1</span><span>5;386:</span><span>1</span><span>34</span><span>1</span><span>)</span>; 10 y of Rx ↑ DFS vs. 5 y of Rx <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>6;375:209)</span></p><p>Adding selective ER degrader (fulvestrant) to AI ↑ OS if mets</p></td></tr><tr><td><p>Ovarian suppress.</p></td><td><p><b>LHRH agonists</b> (eg, leuprolide) or oophorectomy: adjuvant Rx for high risk pre-meno combined with tam. or AI <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>8;379:</span><span>1</span><span>22)</span></p></td></tr><tr><td><p>Cell prolif.</p><p><span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>2;366: 520)</span></p></td><td><p><b>CDK 4/6 inhib</b> (eg, palbociclib, abemaciclib, ribociclib): + AI (preferred 1<sup>st</sup>-line Rx for metastatic dis.) or fulvestrant ↑ PFS in stage IV vs. AI alone <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>8;379:</span><span>1</span><span>926;</span> <span><i>JCO</i></span> <span>20</span><span>1</span><span>7;35:3638)</span></p><p><b>mTOR inhib</b> (everolimus): + AI (exemestane) ↑ OS in stage IV</p></td></tr><tr><td><p>PIK3CA ⊕</p></td><td><p>PI3K inhib</p></td><td><p><b>Alpelisib</b> added to fulvestrant ↑ PFS in metastatic ER/PR ⊕ <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>9;380:</span><span>1</span><span>929)</span></p></td></tr><tr><td><p>HER2 ⊕</p><p><span>(</span><span><i>Lancet</i></span> <span>20</span><span>1</span><span>7;389: 24</span><span>1</span><span>5)</span></p></td><td><p>HER2-targeted</p></td><td><p><b>Trastuzumab</b> (anti-HER2): 1<sup>st</sup>-line Rx combined with chemo</p><p><b>Pertuzumab</b> (prevents HER2 dimerization): + trastuzumab ↑ PFS in adjuvant &amp; metastatic settings <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>7;377:</span><span>1</span><span>22)</span></p><p><b>Trastuzumab emtansine</b> (mAb linked to chemo): ↓ risk of recurrence/death if residual disease post neoadjuvant Rx <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>9;380:6</span><span>1</span><span>7)</span>; preferred 2<sup>nd</sup> line Rx for metastatic disease</p></td></tr><tr><td><p>Stage I–IV (above)</p></td><td><p>Chemo</p></td><td><p><b>Neoadjuvant:</b> conserve breast &amp; evaluate Rx efficacy, equivalent OS as adjuvant <span>(</span><span><i>JCO</i></span> <span>2008;26:778)</span></p><p><b>Adjuvant:</b> calc Oncotype DX score for benefit after surgery in ER/PR⊕ <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>8;379:</span><span>111</span><span>)</span>; use anthracycline ± taxane</p></td></tr><tr><td><p>PDL-1 ⊕ triple ⊖</p></td><td><p>Immune</p></td><td><p><b>PDL-1 Ab</b> (atezolizumab) added to nab-paclitaxel (microtubule inhibitor): ↑ PFS &amp; OS in stage IV <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>8;379:2</span><span>1</span><span>08)</span></p></td></tr><tr><td><p>BRCA ⊕</p></td><td><p>PARP inh</p></td><td><p><b>Olaparib &amp; talazoparib</b> <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>7;377:523 &amp; 20</span><span>1</span><span>8;379:753)</span></p></td></tr><tr><td><p>Triple ⊖</p></td><td><p>Ab-drug conjugate</p></td><td><p>Sacituzumab govitecan: anti-trop-2 linked to chemo ↑ PFS &amp; OS in heavily pre-Rx’d metastatic disease <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>9;380:74</span><span>1</span><span>)</span></p></td></tr></tbody></table>

DFS, disease-free survival; OS, overall survival; PFS, progression-free survival
